CL2014002225A1 - Metodo para elaborar composicion enriquecida en inmunoglobulinas a partir de plasma que comprende co-precipitación de inmunoglobulinas y alfa-1-antitripsina (a1pi); metodo para tratar deficiencia inmune, enfermedad inflamatoria, enfermedad autoinmune o infección aguda. - Google Patents

Metodo para elaborar composicion enriquecida en inmunoglobulinas a partir de plasma que comprende co-precipitación de inmunoglobulinas y alfa-1-antitripsina (a1pi); metodo para tratar deficiencia inmune, enfermedad inflamatoria, enfermedad autoinmune o infección aguda.

Info

Publication number
CL2014002225A1
CL2014002225A1 CL2014002225A CL2014002225A CL2014002225A1 CL 2014002225 A1 CL2014002225 A1 CL 2014002225A1 CL 2014002225 A CL2014002225 A CL 2014002225A CL 2014002225 A CL2014002225 A CL 2014002225A CL 2014002225 A1 CL2014002225 A1 CL 2014002225A1
Authority
CL
Chile
Prior art keywords
a1pi
antitrypsin
immunoglobulins
precipitation
alpha
Prior art date
Application number
CL2014002225A
Other languages
English (en)
Spanish (es)
Inventor
Hans-Peter Schwarz
Wolfgang Teschner
Leopold Bruckschwaiger
Thomas Gundinger
Julia Nuernberger
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47833446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002225(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of CL2014002225A1 publication Critical patent/CL2014002225A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/145Extraction; Separation; Purification by extraction or solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2014002225A 2012-02-23 2014-08-21 Metodo para elaborar composicion enriquecida en inmunoglobulinas a partir de plasma que comprende co-precipitación de inmunoglobulinas y alfa-1-antitripsina (a1pi); metodo para tratar deficiencia inmune, enfermedad inflamatoria, enfermedad autoinmune o infección aguda. CL2014002225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261602488P 2012-02-23 2012-02-23

Publications (1)

Publication Number Publication Date
CL2014002225A1 true CL2014002225A1 (es) 2015-01-16

Family

ID=47833446

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002225A CL2014002225A1 (es) 2012-02-23 2014-08-21 Metodo para elaborar composicion enriquecida en inmunoglobulinas a partir de plasma que comprende co-precipitación de inmunoglobulinas y alfa-1-antitripsina (a1pi); metodo para tratar deficiencia inmune, enfermedad inflamatoria, enfermedad autoinmune o infección aguda.

Country Status (25)

Country Link
US (1) US9782477B2 (cg-RX-API-DMAC7.html)
EP (2) EP4119574A1 (cg-RX-API-DMAC7.html)
JP (1) JP6291423B2 (cg-RX-API-DMAC7.html)
KR (1) KR101930582B1 (cg-RX-API-DMAC7.html)
CN (1) CN104245730B (cg-RX-API-DMAC7.html)
AR (1) AR090425A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013203112B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014020602B1 (cg-RX-API-DMAC7.html)
CA (1) CA2864715A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014002225A1 (cg-RX-API-DMAC7.html)
CO (1) CO7081143A2 (cg-RX-API-DMAC7.html)
DK (1) DK2817334T3 (cg-RX-API-DMAC7.html)
EA (1) EA032478B1 (cg-RX-API-DMAC7.html)
ES (1) ES2928954T3 (cg-RX-API-DMAC7.html)
HU (1) HUE060195T2 (cg-RX-API-DMAC7.html)
IL (1) IL234103B (cg-RX-API-DMAC7.html)
MX (2) MX365236B (cg-RX-API-DMAC7.html)
MY (1) MY167235A (cg-RX-API-DMAC7.html)
NZ (1) NZ628529A (cg-RX-API-DMAC7.html)
PL (1) PL2817334T3 (cg-RX-API-DMAC7.html)
PT (1) PT2817334T (cg-RX-API-DMAC7.html)
SG (1) SG11201405149UA (cg-RX-API-DMAC7.html)
SI (1) SI2817334T1 (cg-RX-API-DMAC7.html)
TW (1) TWI629283B (cg-RX-API-DMAC7.html)
WO (1) WO2013126904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104004091B (zh) * 2014-06-12 2016-08-17 新疆德源生物工程有限公司 一种人免疫球蛋白的制备工艺
CN104004090A (zh) * 2014-06-12 2014-08-27 新疆德源生物工程有限公司 一种人免疫球蛋白的制备方法
GB201413227D0 (en) 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
US10722535B2 (en) 2015-08-13 2020-07-28 Kamada Ltd. Compositions derived from Cohn fraction paste and use thereof
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CA3098609A1 (en) * 2018-05-17 2019-11-21 Csl Behring Ag Method and system of protein extraction
US20230002444A1 (en) * 2019-11-20 2023-01-05 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
US11732004B2 (en) * 2020-04-10 2023-08-22 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
EP4240757A2 (en) * 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
JP2024501025A (ja) * 2020-12-28 2024-01-10 プラズマ テクノロジーズ エルエルシー 免疫グロブリンgのプロセススケールでの単離のためのシステム及び方法
CN118580342B (zh) * 2024-05-20 2025-02-07 广东丹霞生物制药有限公司 一种静脉注射用人免疫球蛋白制剂的制备工艺

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (cg-RX-API-DMAC7.html) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) * 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
CA2232420A1 (en) 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CN1149100C (zh) 1997-10-23 2004-05-12 三菱制药株式会社 可室温贮存的免疫球蛋白静脉注射制剂
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JPWO2003004982A1 (ja) * 2001-07-05 2004-10-28 浜松ホトニクス株式会社 分光装置
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
ES2305845T5 (es) 2003-09-22 2012-04-12 Kamada Ltd. Preparación a gran escala de un inhibidor de proteinasa alfa-1 y su utilización
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
EP1718675B2 (en) 2004-02-27 2017-01-25 Octapharma AG A method of providing a purified, virus safe antibody preparation
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
ES2595059T3 (es) 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
US8546548B2 (en) * 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AT514675B1 (de) 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
US8772462B2 (en) * 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
CN103119058A (zh) 2010-07-23 2013-05-22 巴克斯特国际公司 由血浆生产间-α-抑制蛋白(IAIP)

Also Published As

Publication number Publication date
TW201348248A (zh) 2013-12-01
ES2928954T3 (es) 2022-11-23
DK2817334T3 (da) 2022-10-03
KR20140135996A (ko) 2014-11-27
US9782477B2 (en) 2017-10-10
TWI629283B (zh) 2018-07-11
CO7081143A2 (es) 2014-10-10
US20130224183A1 (en) 2013-08-29
MX2014010076A (es) 2014-09-22
CN104245730A (zh) 2014-12-24
BR112014020602A2 (pt) 2018-09-11
MX365236B (es) 2019-05-28
SI2817334T1 (sl) 2022-11-30
AR090425A1 (es) 2014-11-12
HUE060195T2 (hu) 2023-02-28
MX2019005999A (es) 2019-08-21
WO2013126904A1 (en) 2013-08-29
AU2013203112A1 (en) 2013-09-12
HK1205520A1 (en) 2015-12-18
EP2817334B1 (en) 2022-09-21
PL2817334T3 (pl) 2022-11-21
MY167235A (en) 2018-08-14
BR112014020602B1 (pt) 2022-12-20
JP6291423B2 (ja) 2018-03-14
EP4119574A1 (en) 2023-01-18
JP2015509506A (ja) 2015-03-30
SG11201405149UA (en) 2014-09-26
IL234103B (en) 2019-11-28
NZ628529A (en) 2016-09-30
CN104245730B (zh) 2017-09-01
IL234103A0 (en) 2014-09-30
EP2817334A1 (en) 2014-12-31
AU2013203112B2 (en) 2016-03-10
EA032478B1 (ru) 2019-06-28
EA201491564A1 (ru) 2015-04-30
CA2864715A1 (en) 2013-08-29
PT2817334T (pt) 2022-10-17
KR101930582B1 (ko) 2018-12-18

Similar Documents

Publication Publication Date Title
CL2014002225A1 (es) Metodo para elaborar composicion enriquecida en inmunoglobulinas a partir de plasma que comprende co-precipitación de inmunoglobulinas y alfa-1-antitripsina (a1pi); metodo para tratar deficiencia inmune, enfermedad inflamatoria, enfermedad autoinmune o infección aguda.
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
BR112015008635A2 (pt) anticorpos anti-hiv amplamente neutralizantes.
SMT202000512T1 (it) Anticorpi anti-tau umani
CL2015000173A1 (es) Método para la extracción de litio a partir de solución que incluye litio.
BR112015001596A2 (pt) composição para o tratamento de hiperlipidemia que compreende oxintomodulina.
EP2934404A4 (en) ELASTIC LAMINATE AND METHOD FOR PRODUCING THE ELASTIC LAMINATE
EP3058544A4 (en) Social where next suggestion
PL2852391T3 (pl) Układy do leczenia infekcji płuc
BR112014030067A2 (pt) processo para a fabricação de composição de vapor, e, composição de vapor.
EP3081976A4 (en) Structured illumination microscope, structured illumination method and program
BR112013019150A2 (pt) engenharia do âmbito da imunoglobulina
BR112013029599A2 (pt) sistema de produção de vapor e método
CO6890074A2 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
BR112014032872A2 (pt) processamento de biomassa.
EP2820281A4 (en) CONTINUOUS LOW PRESSURE TUBE WITHOUT TURBINE EXHAUST HOUSING
HRP20181874T1 (hr) Anti-cxcr3 protutijela
FR2994831B1 (fr) Prothese de main.
EP2948832A4 (en) SCALABLE INPUT FROM TRACKED OBJECTS
FR3012515B1 (fr) Aube composite de turbomachine
EP2695154A4 (en) PROVIDING A COMPUTER-BASED LANGUAGE THERAPY
EP2832221A4 (en) HUMANIZED MOUSE
EP2821522A4 (en) METHOD OF MANUFACTURING LAMINATE AND LAMINATE
CL2013000688A1 (es) Procedimiento para obtener una composicion de igg a partir de una composicion de igg parcialmente purificada.
DK2414523T3 (da) Mus med dendtritcelle-forstærket humaniseret immunsystem